MedTrace Logo

Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage

NCT01863706 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2015-03-26

No results posted yet for this study

Summary

Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women. Oxytocin is widely used for prevention of PPH. Some studies suggested misoprostol as an alternative treatment when Oxytocin isn't available. The aim of this study is to compare the safety and efficacy of Oxytocin and misoprostol for prevention of PPH.

Conditions

  • Post Partum Hemorrhage

Interventions

DRUG

Misoprostol

400µg oral misoprostol

DRUG

Oxytocin

20 IU Oxytocin

Sponsors & Collaborators

  • Hormozgan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Minoo Rajaei, Dr · Hormozgan University of Medical Sciences

  • Zohreh Shahboodaghi, Dr · Hormozgan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863706 on ClinicalTrials.gov